Feng Shen
Eastern Hepatobiliary Surgery Hospital
6
6
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jun Xue
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Worked with same sponsors:
Ruiliang Ge
Eastern Hepatobiliary Surgery Hospital
Shared therapeutic areas:
Worked with same sponsors:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Ghassan Abou-Alfa, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Do-Youn Oh, MD, PhD
Seoul National University Hospital
Shared therapeutic areas:
Pierce Chow, MD, PhD
National Cancer Centre, Singapore
Shared therapeutic areas:
Andrew X. Zhu, MD
Massachusetts General Hospital
Shared therapeutic areas:
Antoine ITALIANO, MD, PhD
Institut Bergonié
Shared therapeutic areas:
Kangshun Zhu, Dr.
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Brennan Spiegel, MD, MSHS
Cedars-Sinai Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
All 6 trials loaded